Head and neck cancer treatment in the era of molecular medicine
Adv Cancer Res. 2023;160:205-252. doi: 10.1016/bs.acr.2023.03.004. Epub 2023 Apr 12.ABSTRACTHead and neck cancers are a heterogeneous group of highly aggressive tumors and collectively represent the sixth most common cancer worldwide. Most head and neck cancers are squamous cell carcinomas (HNSCCs). Current multimodal treatment concepts combine surgery, chemotherapy, irradiation, immunotherapy, and targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of HNSCC and revealed novel therapeutic targets and prognostic/predictive biomarkers. Notably, HNSCC is characterized b...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Subramanya Pandruvada Remi Kessler Ann Thai Source Type: research
Applications of tissue-specific and cancer-selective gene promoters for cancer diagnosis and therapy
Adv Cancer Res. 2023;160:253-315. doi: 10.1016/bs.acr.2023.03.005. Epub 2023 Apr 20.ABSTRACTCurrent treatment of solid tumors with standard of care chemotherapies, radiation therapy and/or immunotherapies are often limited by severe adverse toxic effects, resulting in a narrow therapeutic index. Cancer gene therapy represents a targeted approach that in principle could significantly reduce undesirable side effects in normal tissues while significantly inhibiting tumor growth and progression. To be effective, this strategy requires a clear understanding of the molecular biology of cancer development and evolution and develo...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Amit Kumar Swadesh K Das Luni Emdad Paul B Fisher Source Type: research
Mechanical factors driving cancer progression
Adv Cancer Res. 2023;160:61-81. doi: 10.1016/bs.acr.2023.06.002. Epub 2023 Jul 16.ABSTRACTA fundamental step of tumor metastasis is tumor cell migration away from the primary tumor site. One mode of migration that is essential but still understudied is collective invasion, the process by which clusters of cells move in a coordinated fashion. In recent years, there has been growing interest to understand factors regulating collective invasion, with increasing number of studies investigating the biomechanical regulation of collective invasion. In this review we discuss the dynamic relationship between tumor microenvironment ...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Jessanne Y Lichtenberg Sydnie Tran Priscilla Y Hwang Source Type: research
Protein disulfide isomerase family mediated redox regulation in cancer
Adv Cancer Res. 2023;160:83-106. doi: 10.1016/bs.acr.2023.06.001. Epub 2023 Jul 18.ABSTRACTProtein disulfide isomerase (PDI) and its superfamilies are mainly endoplasmic reticulum (ER) resident proteins with essential roles in maintaining cellular homeostasis, via thiol oxidation/reduction cycles, chaperoning, and isomerization of client proteins. Since PDIs play an important role in ER homeostasis, their upregulation supports cell survival and they are found in a variety of cancer types. Despite the fact that the importance of PDI to tumorigenesis remains to be understood, it is emerging as a new therapeutic target in can...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Zhi-Wei Ye Jie Zhang Muhammad Aslam Anna Blumental-Perry Kenneth D Tew Danyelle M Townsend Source Type: research
PFKP: More than phosphofructokinase
Adv Cancer Res. 2023;160:1-15. doi: 10.1016/bs.acr.2023.03.001. Epub 2023 Mar 30.ABSTRACTPhosphofructokinase (PFK) is one of the key enzymes that functions in glycolysis. Studies show that PFKP regulates cell proliferation, apoptosis, autophagy, cell migration/metastasis, and stemness through glycolysis and glycolysis-independent functions. PFKP performs its function not only in the cytoplasm, but also at the cell membrane, on the mitochondria, at the lysosomal membrane, and in the nucleus. The functions of PFKP are extensively studied in cancer cells. PFKP is also highly expressed in certain immune cells; nevertheless, th...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Haizhen Wang Tiffany Penaloza Amanda J Manea Xueliang Gao Source Type: research
Microsomal glutathione transferase 1 in cancer and the regulation of ferroptosis
Adv Cancer Res. 2023;160:107-132. doi: 10.1016/bs.acr.2023.05.001. Epub 2023 Jul 21.ABSTRACTMicrosomal glutathione transferase 1 (MGST1) is a member of the MAPEG family (membrane associated proteins in eicosanoid and glutathione metabolism), defined according to enzymatic activities, sequence motifs, and structural properties. MGST1 is a homotrimer which can bind three molecules of glutathione (GSH), with one modified to a thiolate anion displaying one-third-of-sites-reactivity. MGST1 has both glutathione transferase and peroxidase activities. Each is based on stabilizing the GSH thiolate in the same active site. MGST1 is ...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Jie Zhang Zhi-Wei Ye Ralf Morgenstern Danyelle M Townsend Kenneth D Tew Source Type: research
Lnc-ing epigenetic mechanisms with autophagy and cancer drug resistance
Adv Cancer Res. 2023;160:133-203. doi: 10.1016/bs.acr.2023.03.002. Epub 2023 Apr 7.ABSTRACTLong noncoding RNAs (lncRNAs) comprise a diverse class of RNA molecules that regulate various physiological processes and have been reported to be involved in several human pathologies ranging from neurodegenerative disease to cancer. Therapeutic resistance is a major hurdle for cancer treatment. Over the past decade, several studies has emerged on the role of lncRNAs in cancer drug resistance and many trials have been conducted employing them. LncRNAs also regulate different cell death pathways thereby maintaining a fine balance of ...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Sandhik Nandi Atanu Mondal Aritra Ghosh Shravanti Mukherjee Chandrima Das Source Type: research
Setting sail: Maneuvering SHP2 activity and its effects in cancer
Adv Cancer Res. 2023;160:17-60. doi: 10.1016/bs.acr.2023.03.003. Epub 2023 Apr 17.ABSTRACTSince the discovery of tyrosine phosphorylation being a critical modulator of cancer signaling, proteins regulating phosphotyrosine levels in cells have fast become targets of therapeutic intervention. The nonreceptor protein tyrosine phosphatase (PTP) coded by the PTPN11 gene "SHP2" integrates phosphotyrosine signaling from growth factor receptors into the RAS/RAF/ERK pathway and is centrally positioned in processes regulating cell development and oncogenic transformation. Dysregulation of SHP2 expression or activity is linked to tum...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Colin L Welsh Sarah Allen Lalima K Madan Source Type: research
Head and neck cancer treatment in the era of molecular medicine
Adv Cancer Res. 2023;160:205-252. doi: 10.1016/bs.acr.2023.03.004. Epub 2023 Apr 12.ABSTRACTHead and neck cancers are a heterogeneous group of highly aggressive tumors and collectively represent the sixth most common cancer worldwide. Most head and neck cancers are squamous cell carcinomas (HNSCCs). Current multimodal treatment concepts combine surgery, chemotherapy, irradiation, immunotherapy, and targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of HNSCC and revealed novel therapeutic targets and prognostic/predictive biomarkers. Notably, HNSCC is characterized b...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Subramanya Pandruvada Remi Kessler Ann Thai Source Type: research
Applications of tissue-specific and cancer-selective gene promoters for cancer diagnosis and therapy
Adv Cancer Res. 2023;160:253-315. doi: 10.1016/bs.acr.2023.03.005. Epub 2023 Apr 20.ABSTRACTCurrent treatment of solid tumors with standard of care chemotherapies, radiation therapy and/or immunotherapies are often limited by severe adverse toxic effects, resulting in a narrow therapeutic index. Cancer gene therapy represents a targeted approach that in principle could significantly reduce undesirable side effects in normal tissues while significantly inhibiting tumor growth and progression. To be effective, this strategy requires a clear understanding of the molecular biology of cancer development and evolution and develo...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Amit Kumar Swadesh K Das Luni Emdad Paul B Fisher Source Type: research
Mechanical factors driving cancer progression
Adv Cancer Res. 2023;160:61-81. doi: 10.1016/bs.acr.2023.06.002. Epub 2023 Jul 16.ABSTRACTA fundamental step of tumor metastasis is tumor cell migration away from the primary tumor site. One mode of migration that is essential but still understudied is collective invasion, the process by which clusters of cells move in a coordinated fashion. In recent years, there has been growing interest to understand factors regulating collective invasion, with increasing number of studies investigating the biomechanical regulation of collective invasion. In this review we discuss the dynamic relationship between tumor microenvironment ...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Jessanne Y Lichtenberg Sydnie Tran Priscilla Y Hwang Source Type: research
Protein disulfide isomerase family mediated redox regulation in cancer
Adv Cancer Res. 2023;160:83-106. doi: 10.1016/bs.acr.2023.06.001. Epub 2023 Jul 18.ABSTRACTProtein disulfide isomerase (PDI) and its superfamilies are mainly endoplasmic reticulum (ER) resident proteins with essential roles in maintaining cellular homeostasis, via thiol oxidation/reduction cycles, chaperoning, and isomerization of client proteins. Since PDIs play an important role in ER homeostasis, their upregulation supports cell survival and they are found in a variety of cancer types. Despite the fact that the importance of PDI to tumorigenesis remains to be understood, it is emerging as a new therapeutic target in can...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Zhi-Wei Ye Jie Zhang Muhammad Aslam Anna Blumental-Perry Kenneth D Tew Danyelle M Townsend Source Type: research
PFKP: More than phosphofructokinase
Adv Cancer Res. 2023;160:1-15. doi: 10.1016/bs.acr.2023.03.001. Epub 2023 Mar 30.ABSTRACTPhosphofructokinase (PFK) is one of the key enzymes that functions in glycolysis. Studies show that PFKP regulates cell proliferation, apoptosis, autophagy, cell migration/metastasis, and stemness through glycolysis and glycolysis-independent functions. PFKP performs its function not only in the cytoplasm, but also at the cell membrane, on the mitochondria, at the lysosomal membrane, and in the nucleus. The functions of PFKP are extensively studied in cancer cells. PFKP is also highly expressed in certain immune cells; nevertheless, th...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Haizhen Wang Tiffany Penaloza Amanda J Manea Xueliang Gao Source Type: research
Microsomal glutathione transferase 1 in cancer and the regulation of ferroptosis
Adv Cancer Res. 2023;160:107-132. doi: 10.1016/bs.acr.2023.05.001. Epub 2023 Jul 21.ABSTRACTMicrosomal glutathione transferase 1 (MGST1) is a member of the MAPEG family (membrane associated proteins in eicosanoid and glutathione metabolism), defined according to enzymatic activities, sequence motifs, and structural properties. MGST1 is a homotrimer which can bind three molecules of glutathione (GSH), with one modified to a thiolate anion displaying one-third-of-sites-reactivity. MGST1 has both glutathione transferase and peroxidase activities. Each is based on stabilizing the GSH thiolate in the same active site. MGST1 is ...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Jie Zhang Zhi-Wei Ye Ralf Morgenstern Danyelle M Townsend Kenneth D Tew Source Type: research
Lnc-ing epigenetic mechanisms with autophagy and cancer drug resistance
Adv Cancer Res. 2023;160:133-203. doi: 10.1016/bs.acr.2023.03.002. Epub 2023 Apr 7.ABSTRACTLong noncoding RNAs (lncRNAs) comprise a diverse class of RNA molecules that regulate various physiological processes and have been reported to be involved in several human pathologies ranging from neurodegenerative disease to cancer. Therapeutic resistance is a major hurdle for cancer treatment. Over the past decade, several studies has emerged on the role of lncRNAs in cancer drug resistance and many trials have been conducted employing them. LncRNAs also regulate different cell death pathways thereby maintaining a fine balance of ...
Source: Advances in Cancer Research - September 13, 2023 Category: Cancer & Oncology Authors: Sandhik Nandi Atanu Mondal Aritra Ghosh Shravanti Mukherjee Chandrima Das Source Type: research
